Abstract: The present invention provides an in vitro method for obtaining data useful for diagnosing a cardiomyopathy in a human subject, wherein the method comprises using, as an indicator, the expression levels, obtained from a biological sample isolated from the human subject, preferably a plasma sample, of one or more of the following miRNAs miR-721 and/or miR-155); and obtaining a result of the method by comparing the expression levels of said one or more miRNAs with a reference value or with the expression levels of a control, indicator of the absence of cardiomyopathy.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
October 4, 2022
Assignee:
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Inventors:
María Pilar Martín Fernández, Raquel Sánchez Díaz, Adela Matesanz Marín, Luis Jesús Jiménez Borreguero, Francisco Sánchez Madrid
Abstract: The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).
Type:
Grant
Filed:
December 30, 2016
Date of Patent:
February 2, 2021
Assignees:
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.), Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid
Inventors:
Juan Miguel Redondo Moya, Nerea Méndez-Barbero, Jorge Oller Pedrosa, Miguel Ramón Campanero García